PFE240705P31500
- 4.35
- 0.000.00%
Pfizer Newsroom
Barclays Maintains Equal-Weight on Pfizer, Raises Price Target to $30
Barclays analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Equal-Weight and raises the price target from $28 to $30.
Cantor Fitzgerald Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $45
Cantor Fitzgerald analyst Louise Chen maintains $Pfizer(PFE.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of 40.2% and a
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Pfizer (PFE)
Parnassus Value Equity Fund's Strategic Moves in Q2 2024: A Deep Dive Into Micron Technology's ...
Pfizer Options Spot-On: On July 10th, 105.18K Contracts Were Traded, With 2.81 Million Open Interest
On July 10th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 105.18K options for the day, of which put options accounted for 24.66% of the total transactions, and
Pfizer Seeks New Chief Scientific Officer as Dolsten Departs
Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
This week, Pfizer Inc (NYSE:PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. (
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
Pfizer Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 60.03% Cantor Fitzgerald $45 → $45 Reiterates Overweight → Overweight 07/01/2024 60.03%
Sector Update: Health Care Stocks Steady Premarket Wednesday
Health care stocks were steady premarket Wednesday as the Health Care Select Sector SPDR Fund (XLV) was up 0.03% and the iShares Biotechnology ETF (IBB) was recently inactive.Illumina (ILMN) rose 4%
Pfizer, Evotec Ink Drug Discovery Deal
Express News | Pfizer : Barclays Raises Target Price to $30 From $28
Barclays Maintains Pfizer(PFE.US) With Hold Rating, Raises Target Price to $30
Barclays analyst Gena Wang maintains $Pfizer(PFE.US)$ with a hold rating, and adjusts the target price from $28 to $30.According to TipRanks data, the analyst has a success rate of 46.2% and a total
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
J.P. Morgan analyst Chris Schott maintains $Pfizer(PFE.US)$ with a hold rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 50.2% and a total
Evotec, Pfizer Team Up for Early Drug Discovery for Metabolic, Infectious Diseases
Evotec (EVT.F) and pharmaceutical company Pfizer (PFE.F) entered into a multi-year master research collaboration and option and license agreement to conduct early discovery research for metabolic
Express News | Evotec SE Shares up 2.3% After Collaboration Agreement With Pfizer
Evotec and Pfizer Collaborate to Advance Drug Discovery in France
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseasesHAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(
Express News | Evotec SE Shares up 5.1% in Lang & Schwarz Pre-Market Trade After Collaboration Agreement With Pfizer
Pfizer Options Spot-On: On July 9th, 130.02K Contracts Were Traded, With 2.76 Million Open Interest
On July 9th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 130.02K options for the day, of which put options accounted for 40.12% of the total transactions, and call
Unusual Options Activity: TEVA, MAT and Others Attract Market Bets, TEVA V/OI Ratio Reaches 347.7
EST Jul 9th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options